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Objectives: Prior research has estimated the burden of opioid abuse in the 
U.S. However, older data may not reflect recent trends in abuse prevalence and 
associated costs. This study provides updated estimates of the burden of opioid 
abuse. MethOds: Patients aged 12-64 diagnosed with opioid abuse/dependence 
(“abusers”) were selected from the Truven MarketScan medical and pharmacy 
claims database, 2009-2012. A 12-month follow-up period centered on the index 
date (i.e., first abuse diagnosis) was used to assess costs and was preceded by a 
6-month baseline period. Patients were required to have continuous non-HMO cov-
erage throughout the 18-month study period. Potential controls met similar inclu-
sion criteria but were not diagnosed with abuse, with their index date based on a 
random medical claim. Abusers were matched 1:1 to controls based on index year, 
baseline health care costs, and propensity score to account for baseline differences. 
Per-patient health care costs of abusers and matched controls were compared to 
determine the excess annual health care costs of diagnosed abuse. Costs reflect 
payments from payers to providers in 2012USD. Prevalence of abuse was estimated 
as the proportion of abusers among those with ≥ 1 one month of eligibility in a given 
year. Results: 38,876 abusers and 955,202 controls met the inclusion criteria. 35,828 
(92.2%) abusers were successfully matched. Post-matching, baseline characteristics 
were well-balanced. Abusers had $11,319 higher annual total health care costs than 
matched controls ($22,132 vs. $10,813) in the follow-up period. Costs were higher 
for abusers in all cost categories: inpatient, emergency department, outpatient, and 
prescription drug costs [all p-values < 0.001]. Diagnosed abuse prevalence increased 
from 0.16% in 2009 to 0.27% in 2012. cOnclusiOns: We find substantial excess 
health care costs of opioid abuse, consistent with prior research. The rising preva-
lence of abuse suggests a growing economic burden but may also reflect increased 
physician awareness of previously undiagnosed patients.
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Objectives: Binge eating disorder (BED), the most common eating disorder, lacks 
a specific ICD-9 diagnosis code. With BED subsumed under “eating disorder not 
otherwise specified (EDNOS),” which includes other disorders, patient identification 
using medical claims data is problematic. This study used natural language pro-
cessing (NLP) to identify patients with BED and compared their health care costs to 
patients with EDNOS without BED (EDNOS-only) and to matched-patients without 
an eating disorder (Non-ED). MethOds: An NLP algorithm identified adults with 
BED from clinical notes in the Veterans Health Administration electronic health 
record database from 2005-2011 . EDNOS-only patients were identified using ICD-9 
code (307.50) and those with NLP-identified BED were excluded. The first diagno-
sis date defined the index date for both groups. Non-ED patients were randomly 
matched up to 4:1 to patients with BED, matched on age, sex, BMI, depression diag-
nosis, and index month. Total health care, inpatient, outpatient, and pharmacy 
costs were examined and reported in 2011 US$. Generalized linear models were 
used to compare total one-year health care costs while adjusting for patient char-
acteristics, including baseline costs. Results: There were 257 BED, 760 EDNOS-
only, and 823 matched Non-ED patients identified. The mean (SD) total unadjusted 
one-year costs were $33,716 ($38,928) for BED, $37,052 ($40,719) for EDNOS-only, 
and $19,548 ($35,780) for Non-ED patients. The largest component of costs for each 
was pharmacy (BED $21,842, EDNOS-only $26,426, and Non-ED $12,062) followed 
by inpatient (BED $8,483, EDNOS-only $5,892, and Non-ED $4,079) and outpatient 
costs (BED $3,391, EDNOS-only $4,735, and Non-ED $3,407). When adjusting for 
patient characteristics, BED patients had one-year total health care costs $5,589 
higher than EDNOS-only (p= 0.06) and $18,152 higher than matched Non-ED patients 
(p< 0.001). cOnclusiOns: Patients with BED had comparable costs to EDNOS 
patients and significantly higher adjusted costs than Non-ED patients. BED patients 
comprise a population with high clinical burden and health care utilization.
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Objectives: Opioid abuse is associated with annual per-patient excess health care 
costs exceeding $20,000. Some patients have considerably higher costs, however, 
and little is known about their characteristics. This study examined the charac-
teristics of high-cost patients diagnosed with opioid abuse. MethOds: Patients 
aged 12-64 diagnosed with opioid abuse/dependence (“abuse”) were identified in 
OptumHealth Reporting and Insights medical and pharmacy claims data, 2006-2012. 
Patients were required to have continuous non-HMO coverage over a 12-month 
follow-up period centered on an index date (i.e., date of first abuse diagnosis) and 
a 6-month baseline period preceding the follow-up period. Patients in the top 20% 
of total health care costs in the follow-up period were classified as “high-cost,” with 
the remainder considered “low-cost.” Patient characteristics and health care costs 
were compared between high-cost and low-cost patients using chi-squared tests 
and Wilcoxon rank-sum tests. Results: 9,291 patients diagnosed with abuse were 
identified (1,859 high-cost patients; 7,432 low-cost patients). High-cost patients were 
older (42.5 vs. 36.1; p< 0.001) and more likely to be female (55.9% vs. 42.9%%; p< 0.001). 
They had a higher comorbidity burden at baseline, as reflected in the Charlson 
Comorbidity Index (0.8 vs. 0.2; p< 0.001). High-cost patients also had higher rates 
of non-opioid substance abuse diagnoses (12.4% vs. 8.9%; p< 0.001) and psychotic 
response to response during the titration period was estimated using the predicted 
treatment response rates estimated by a previously published matching-adjusted 
indirect comparison (MAIC); mean change in ADHD-RS-IV total score from base-
line to endpoint was the efficacy outcome. The incidence rates of adverse events 
were based on those observed in the clinical trials included in the MAIC. Analyses 
were conducted from both a societal and a Canadian Ministry of Health (MoH) 
perspective over a 1-year time horizon with weekly cycles. Deterministic and 
probabilistic sensitivity analyses (PSA) were conducted to assess the robustness 
of the base-case results. Results: Compared with ATX, GXR was a dominant 
strategy (lower cost and improved efficacy) from a societal perspective, while it 
was associated with an incremental cost-effectiveness ratio (ICER) of $57,866/
QALY from a Canadian MoH perspective. Results of the PSA indicated that the 
ICER remains below the $50,000 willingness to pay threshold in 93.4% and 61.3% 
of the simulations from a societal and a Canadian MoH perspective, respec-
tively. cOnclusiOns: This analysis found that GXR was cost-effective relative 
to ATX in a majority of scenarios and perspectives in the treatment of children 
and adolescents with ADHD in Canada.
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Objectives: Attention-deficit/hyperactivity disorder (ADHD) is a common 
childhood disorder with a global prevalence of 2.2 to 17.8%. In the case of an 
inadequate response to stimulant medication, a combination therapy of stimu-
lants and adjunctive medication may improve the control of ADHD symptoms, 
reduce dose-limiting adverse events, and help manage comorbidities. The objec-
tive was to assess the economic impact of guanfacine extended-release (GXR) 
in combination with long-acting stimulants compared to long-acting stimulant 
monotherapy in the treatment of children and adolescents with ADHD from a 
Canadian perspective. MethOds: A Markov model was developed to assess the 
cost-effectiveness of GXR in combination with a long-acting stimulant compared 
to long-acting stimulant monotherapy. Health states were defined based on the 
clinician-reported Clinical Global Impressions-Severity (normal, mild, moder-
ate, and severe). Transition probabilities were calculated based on patient-level 
data from a published study. Long-acting stimulants available in Canada were 
considered in the base-case model: amphetamine mixed salts, methylphenidate 
HCl formulations, and lisdexamfetamine dimesylate. Analyses were conducted 
from both a Canadian Ministry of Health (MoH) and a societal perspective over 
a 1-year time horizon with weekly cycles. Deterministic and probabilistic sensi-
tivity analyses (PSA) were conducted to assess the robustness of the base-case 
results. Results: Compared to long-acting stimulant monotherapy, GXR with a 
long-acting stimulant was associated with incremental cost-effectiveness ratios 
of $23,720/QALY and $11,845/QALY from a Canadian MoH and a societal perspec-
tive, respectively. PSA of GXR as an adjunctive therapy to long-acting stimulants 
showed that it remains a cost-effective strategy in 100% of the simulations from 
both perspectives in numerous sensitivity analyses, according to a willingness to 
pay of $50,000/QALY. cOnclusiOns: This economic evaluation demonstrates that 
GXR as an adjunctive therapy to a long-acting stimulant is a cost-effective strategy 
compared to long-acting stimulant monotherapy in the treatment of children and 
adolescents with ADHD in Canada.
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Objectives: This real-world retrospective study aims at comparing re-hospitali-
zation patterns and costs among patients with schizophrenia receiving paliperi-
done palmitate (PP) or oral antipsychotics (AP) in an inpatient setting. MethOds: 
Hospital discharge and billing records from the Premier Perspective Comparative 
Hospital Database were analyzed for adult patients who had a schizophrenia-related 
hospitalization with either PP or oral AP treatment (index hospitalization) between 
1/2009 and 3/2012 and no evidence of prior treatment with other long-acting AP. 
Inverse probability of treatment weights (IPTW) based on propensity scores were 
used to weight cohorts in order to reduce confounding. Patients treated with PP 
during their index hospitalization were compared to those treated with oral AP in 
terms of re-hospitalizations and ER visits using the Andersen-Gill Cox extension 
of multivariate Cox proportional hazard models. Hospital costs (re-hospitaliza-
tions, ER, and hospital outpatient visits) of patients treated with PP were com-
pared to those of patients treated with oral AP using a multivariate generalized 
linear model regression that was weighted by the combined weight of the IPTW 
and the observation period length. Results: After applying IPTW, weighted mean 
age was 43.4 years for PP (N= 374; N weighted= 19,526) and 45.6 years for oral AP 
(N= 45,251; N weighted= 26,099) patients. The risk of all-cause re-hospitalizations 
or ER visits was significantly lower for the PP cohort compared to the oral AP cohort 
(hazard ratio [HR], [95%CI] = 0.61, [0.59;0.63] p< .0001). Similarly, hospital costs six 
months after index hospitalization were lower for the PP cohort compared to the 
oral AP cohort (adjusted mean monthly cost difference [95%CI]: - $404[-781;-148], 
p< .0001). cOnclusiOns: This hospital database analysis using the IPTW method 
found that, compared with oral AP, PP was associated with a lower risk of an ER visit 
and re-hospitalization in patients with schizophrenia receiving antipsychotics in 
the hospital setting, resulting in lower hospital costs.
